Losartan therapy for cardiac disease in paediatricMarfan syndrome

Journal of Paediatrics and Child Health
Lisa J EwansLesley Adès

Abstract

A case of severe early-onset Marfan syndrome (MFS) led us to ask the question: 'Should an ARB, particularly losartan [intervention], compared with beta blockade alone [comparison], be commenced in all paediatric MFS patients [patient] with aortic root dilatation [outcome]?' The current literature was critically appraised to address this question.

References

Nov 3, 1993·JAMA : the Journal of the American Medical Association·A D OxmanG H Guyatt
Apr 24, 1996·American Journal of Medical Genetics·A De PaepeR E Pyeritz
Jul 13, 2006·International Journal of Cardiology·Deborah R GersonyWelton M Gersony
Dec 26, 2006·The Journal of Pediatrics·Elif Seda Selamet TierneyWelton M Gersony
Jun 27, 2008·The New England Journal of Medicine·Benjamin S BrookeHarry C Dietz
Jul 2, 2010·Journal of Medical Genetics·Bart L LoeysAnne M De Paepe
May 13, 2011·Revista española de cardiología·Alberto FortezaDavid García-Dorado
Sep 4, 2013·European Heart Journal·Maarten GroeninkBarbara J M Mulder
Feb 4, 2014·The American Journal of Cardiology·Howard P Gutgesell
Mar 1, 2014·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Gretchen MacCarrickHarry C Dietz

❮ Previous
Next ❯

Citations

Oct 28, 2019·Proceedings·Renita A ThomasSaradha Subramanian

❮ Previous
Next ❯

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.